Rising Prevalence of CVDs Leads to Increasing Demand for Cardiac Biomarkers

In 2021, the cardiac biomarkers industry contributes $8,459.6 million, and it is projected to rise at a rate of 10.5%, to capture $20,718.8 million revenue in 2030. It is led by the rising prevalence of acute coronary syndrome, increasing point-of-care testing kit demand, and technological advancements in the industry.

Moreover, the surging investments in biomarker research, increasing CVDs incidences, and rising geriatric population are projected to boost the industry growth.

To receive free sample pages of this report@ https://www.psmarketresearch.com/market-analysis/cardiac-biomarker-market/report-sample

Troponin holds a significant share of the industry, accounting for 35%, and it is projected to experience significant growth in the coming years. It is due to extraordinary specifications, and protein complex capacity to help in diagnosing cardiac problems, such as ACS, precisely.

Around 18 million deaths worldwide are caused by cardiac vascular diseases each year, which accounts for 31% of all fatalities. Therefore, companies are focusing to offer test kits to facilitate the biomarkers detection for a better understanding of CVDs pathogenesis. Some of the major biomarkers are C-reactive protein (CRP), lipoprotein-associated phospholipase A2, N-terminal prohormone BNP, and cystatin C. Moreover, the surging use of biomarkers in ACS diagnosis and risk assessment proliferates the industry growth.

In addition, laboratory testing captures a substantial share of the industry, accounting for 60%, and it is projected to retain its position in the near future. It is led by increasing healthcare expenditure, reforms for improving the healthcare infrastructure, surging disposable incomes as well as initiatives of private and government sectors for the prevention of heart diseases.

Enquire before purchase@ https://www.psmarketresearch.com/send-enquiry?enquiry-url=cardiac-biomarker-market

Moreover, point-of-care testing is projected to experience substantial growth in the near future, led by its increased adoption by healthcare professionals for patient monitoring, in cases of chest pain in critical care centers.
Moreover, the growing demand for biomarker tests for early diagnosis of conditions that may cause a major cardiac event leads to cardiac biomarkers industry propulsion.

Furthermore, North America captures the largest share of the cardiac biomarkers industry, accounting for 35%. It is ascribed to the extensive precision medicine usage of the biomarkers, and growing adoption of biomarkers for cardiac disease diagnosis.

Therefore, the rising prevalence of CVDs, with growing incidences of death caused by heart failures, leads to increasing demand for cardiac biomarkers for early diagnosis of the conditions.

Browse More Reports Published by P&S

Global Cardiac Monitoring Market Size Analysis - https://www.psmarketresearch.com/market-analysis/cardiac-monitoring-market

Global Digital Biomarkers Market Size - https://www.psmarketresearch.com/market-analysis/digital-biomarkers-market

Global Aortic Valve Market Size - https://www.psmarketresearch.com/market-analysis/aortic-valve-market

Global Precision Cardiology Market Size Analysis - https://www.psmarketresearch.com/market-analysis/precision-cardiology-market

About P&S Intelligence

P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.

Contact:
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.